About FibroGen
FibroGen is a company based in San Francisco (United States) founded in 1993 by Rory Riggs. FibroGen has raised $215.5 million across 8 funding rounds from investors including Goldman Sachs, T. Rowe Price and Janus Henderson Investors. The company has 225 employees. FibroGen offers products and services including Roxadustat and FG-3246. FibroGen operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
- Headquarter San Francisco, United States
- Employees 225
- Founders Rory Riggs
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website fibrogen.com
- Social LinkedIn X
- Legal Name Fibrogen, Inc
- Annual Revenue$29.62 M (USD)-36.71as on Dec 31, 2024
- Net Profit-$47.58 M (USD)83.26as on Dec 31, 2024
- EBITDA-$128.27 M (USD)57.27as on Dec 31, 2024
- Total Equity Funding$215.5M (USD)
in 8 rounds
- Latest Funding Round$20M (USD), Post-IPO
Dec 2014
- InvestorsGoldman Sachs
& 14 more
- Employee Count225
Products & Services of FibroGen
FibroGen offers a comprehensive portfolio of products and services, including Roxadustat and FG-3246.
Drug for treating anemia associated with chronic kidney disease
Therapy targeting prostate cancer through targeted mechanisms
Funding Insights of FibroGen
FibroGen has successfully raised a total of $215.5M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $215.5M
- Total Rounds 8
- Last Round Post-IPO — $20M
- First Round $1.98M
(Aug 2002)
- Investors Count 15
All 8 funding rounds of FibroGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2014 | $20M | Post-IPO | – | – | – |
| Apr 2007 | $15M | Series D | – | – | – |
| Jan 2007 | $50M | Series D | – | – | – |
| Nov 2005 | $9.78M | Series C | – | – | – |
| Feb 2005 | $107.25M | Series C | – | Adage Capital Management | |
| Mar 2004 | $25M | Series B | – | – | – |
| Sep 2002 | $6.5M | Series A | – | – | – |
| Aug 2002 | $1.98M | Unspecified | – | – | – |
15 investors in total: 15 institutional.
Investors in FibroGen
FibroGen has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, T. Rowe Price and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Biotechnology investments are targeted by the venture capital firm. | – | merlinbiomed.com | New York, United States | |
Early-stage life sciences startups are funded by Bio Fund Management. | – | biofund.fi | Helsinki, Finland | |
Investment banking services are delivered across multiple financial sectors. | 1869 | goldmansachs.com | New York, United States | |
Single family office of H.L. Hunt and Lyda based out of Texas | – | rosewd.com | Dallas, United States | |
Venture capital fund focused on investing in multiple sectors | – | baincapitalventures.com | Boston, United States | |
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
Delivers comprehensive financial services solutions for clients. | 2001 | smbc-cm.com | Hong Kong, China | |
Opportunistic strategies in real estate are pursued by the fund. | 1994 | ozm.com | New York, United States |
Investor details for FibroGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of FibroGen
64 people are tracked at FibroGen (38 in leadership, 26 in team); the tracked headcount is 225.
| Name | Role | Group |
|---|---|---|
Rory Riggs | Co-Founder | Leadership |
Michael D. Lowenstein | Chief Legal Officer | Leadership |
Lauren Kury | Director Supply Chain Planning / Roxadustat CMC Team Lead | Leadership |
Ewa Carrier | Vice President Clinical Development | Leadership |
Michelle Simonetti | Executive Director, HR Operations, Compensation & Benefits | Leadership |
Mark Lonergan | Vice President, Manufacturing And Supply Operations | Leadership |
Ginny Kosor | Executive Director Of Facilities Operations | Leadership |
James Wang | Accounting Director | Leadership |
Cristina T. | Associate Director, People Operations (remote) | Leadership |
Pat Cotroneo | CFO | Leadership |
Leanne C. Price | Chief Intellectual Property Officer | Leadership |
Percy H. Carter | Chief Scientific Officer | Leadership |
Marci Lillis | Vice President, Intellectual Property | Leadership |
Thane Wettig | Chief Executive Officer | Leadership |
Dr. Olga V. Gambetti M.D., Ph.D., Drmedsci | Medical Director, Clinical Development | Leadership |
Lori S. | Executive Medical Director, Clinical Development | Leadership |
Rachel Yin | Executive Director, Head Of Tax | Leadership |
Chris Newman | Executive Director Business Development | Leadership |
Carol Gaddum | Executive Director, Forecasting, Analytics & New Product Planning | Leadership |
Claudia Witschi | Executive Director, Head Analytical Development And Drug Product | Leadership |
44 more people are available in the full profile.
Complete people profiles for FibroGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of FibroGen
FibroGen is a publicly listed company on the NASDAQ with ticker symbol FGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Nov 2014
- Listed onNASDAQ: FGEN
- Listed entityFibroGen, Inc
- Exchange sectorHealth technology
- ISINUS31572Q8814
- Share price$9.71 (+7.65% on the day) · 2026-01-08
- Market capitalisation$39.3M
- Price to earnings0.2
- EPS (diluted, trailing year)$40.44
- Volume (last session)34,233
- Analyst consensusBuy
Financials of FibroGen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $29.6M | -$47.6M | -$128.3M |
| 2023 | $46.8M | -$284.2M | -$300.2M |
| 2022 | $140.7M | -$293.6M | -$290.4M |
| 2021 | $235.3M | -$290.0M | -$273.7M |
| 2020 | $176.3M | -$189.3M | -$169.8M |
Detailed financial statements for FibroGen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of FibroGen
4 dated milestones of FibroGen across 21 years, from founding to its latest funding, stage changes and deals.
- Founded FibroGen is founded.
- Funding First funding round of $2.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.0M.
Competitors of FibroGen
FibroGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| regeneron.com | 1988 | Tarrytown, United States | – | 13,450 | Antibodies are developed for treating cancer, eye, and inflammatory diseases. | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. |
Detailed competitors of FibroGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of FibroGen
The website of FibroGen (fibrogen.com) receives about 6.2K visits a month and ranks #2,827,257 among all websites worldwide, #3,793 in Biotechnology and Pharmaceuticals.
- Monthly visits6.2K
▼ 17.3% vs previous month
- Unique visitors3.1K
per month
- Global rank#2,827,257
among all websites
- Category rank#3,793
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.7
- Average visit30 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with FibroGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cellarity.com | 100% | 5.8K | #2,884,812 | View details | |
| edqm.eu | 98% | – | #199,638 | View details | |
| proqinase.com | 98% | 1.1K | #9,480,081 | View details | |
| codexis.com | 98% | 6.2K | #3,137,247 | View details | |
| trinitybiotech.com | 64% | 9.3K | #2,475,266 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for FibroGen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Fibrogen
Complete news archive for FibroGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to FibroGen
10 companies that operate in the same segment as FibroGen (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 | |
Immunotherapeutics for cancer treatment are developed to target solid tumors. | 2017 | San Diego, California, United States | USD 181 M | USD 10 M | 81 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about FibroGen
FibroGen was founded in 1993 and raised its 1st funding round 9 years after it was founded.
FibroGen is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
FibroGen is a funded company, having raised a total of $215.5M across 8 funding rounds to date. The company's 1st funding round was a Unspecified of $1.98M, raised on Aug 2002.
FibroGen has 225 employees.
Annual revenue of FibroGen is $29.62M as on Dec 31, 2024.
FibroGen was founded in 1993 and is headquartered in San Francisco, United States, within the biotechnology sector. Clinical programs in anemia, fibrosis, and oncology have been established through research on connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. FG-4592, an oral HIF prolyl hydroxylase inhibitor, is advanced for anemia associated with chronic kidney disease. FG-3019, a monoclonal antibody, targets idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis.
FibroGen's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
FibroGen offers Roxadustat and FG-3246.
Yes, FibroGen is publicly traded on NASDAQ under the ticker symbol FGEN.
FibroGen has 15 investors. Key investors include Goldman Sachs, T. Rowe Price, Janus Henderson Investors, Sigma Capital Group, and Oz Management.
FibroGen operates through Fibrogen Inc.